MILANO VINCENT — SEC insider filings

SEC reporting owner CIK 1187159. 40 insider filings on record with FilingPulse; latest filed 2026-09-02.

Transaction summary — filings shown

Covers all 40 filings on record, filed 2020-12-22 to 2026-09-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Aceragen, Inc. (ACGN)Director8—4 legs · 46,402 sh · $186,4506
BIOCRYST PHARMACEUTICALS INC (BCRX)Director252 legs · 22,500 sh · $185,175—28
Aclaris Therapeutics, Inc. (ACRS)Director7——22

Insider filings — MILANO VINCENT

FiledFormIssuerReported transactionsSource
2026-09-024BIOCRYST PHARMACEUTICALS INC (BCRX)Grant/award (A): 1,159 @ $9.70EDGAR
2026-06-154BIOCRYST PHARMACEUTICALS INC (BCRX)Grant/award (A): 15,294 @ $0 · Grant/award (A): 33,540 (derivative) @ $0EDGAR
2026-06-084Aclaris Therapeutics, Inc. (ACRS)Option exercise (M): 11,580 · Grant/award (A): 42,350 (derivative) @ $0 · Grant/award (A): 10,987 (derivative) @ $0 · Option exercise (M): 11,580 (derivative) @ $0EDGAR
2026-06-024BIOCRYST PHARMACEUTICALS INC (BCRX)Grant/award (A): 1,122 @ $8.91EDGAR
2026-03-034BIOCRYST PHARMACEUTICALS INC (BCRX)Grant/award (A): 848 @ $8.75EDGAR
2025-12-024BIOCRYST PHARMACEUTICALS INC (BCRX)Grant/award (A): 783 @ $7.18EDGAR
2025-09-034BIOCRYST PHARMACEUTICALS INC (BCRX)Grant/award (A): 676 @ $8.31EDGAR
2025-06-164BIOCRYST PHARMACEUTICALS INC (BCRX)Grant/award (A): 12,500 @ $0 · Grant/award (A): 27,181 (derivative) @ $0EDGAR
2025-06-094Aclaris Therapeutics, Inc. (ACRS)Option exercise (M): 4,793 · Grant/award (A): 42,350 (derivative) @ $0 · Grant/award (A): 11,580 (derivative) @ $0 · Option exercise (M): 4,793 (derivative) @ $0EDGAR
2025-06-034BIOCRYST PHARMACEUTICALS INC (BCRX)Grant/award (A): 523 @ $10.75EDGAR
2025-03-044BIOCRYST PHARMACEUTICALS INC (BCRX)Grant/award (A): 653 @ $8.61EDGAR
2024-12-024BIOCRYST PHARMACEUTICALS INC (BCRX)Grant/award (A): 750 @ $7.50EDGAR
2024-09-034BIOCRYST PHARMACEUTICALS INC (BCRX)Grant/award (A): 647 @ $8.69EDGAR
2024-06-144BIOCRYST PHARMACEUTICALS INC (BCRX)Grant/award (A): 6,820 @ $0 · Grant/award (A): 49,933 (derivative) @ $0EDGAR
2024-06-104Aclaris Therapeutics, Inc. (ACRS)Grant/award (A): 15,750 (derivative) @ $0 · Grant/award (A): 4,793 (derivative) @ $0EDGAR
2024-06-044Aclaris Therapeutics, Inc. (ACRS)Option exercise (M): 4,660 · Option exercise (M): 4,660 (derivative) @ $0EDGAR
2024-06-034BIOCRYST PHARMACEUTICALS INC (BCRX)Grant/award (A): 870 @ $6.46EDGAR
2024-05-224BIOCRYST PHARMACEUTICALS INC (BCRX)Purchase (P): 15,000 @ $6.25EDGAR
2024-03-044BIOCRYST PHARMACEUTICALS INC (BCRX)Grant/award (A): 999 @ $5.63EDGAR
2023-12-014BIOCRYST PHARMACEUTICALS INC (BCRX)Grant/award (A): 956 @ $5.88EDGAR
2023-09-054BIOCRYST PHARMACEUTICALS INC (BCRX)Grant/award (A): 791 @ $7.11EDGAR
2023-08-114Aceragen, Inc. (ACGN)Sale (S): 3,283 @ $0.53EDGAR
2023-06-154BIOCRYST PHARMACEUTICALS INC (BCRX)Grant/award (A): 16,745 @ $0 · Grant/award (A): 39,072 (derivative) @ $0EDGAR
2023-06-054Aclaris Therapeutics, Inc. (ACRS)Option exercise (M): 4,507 · Grant/award (A): 15,750 (derivative) @ $0 · Grant/award (A): 4,660 (derivative) @ $0 · Option exercise (M): 4,507 (derivative) @ $0EDGAR
2023-06-024BIOCRYST PHARMACEUTICALS INC (BCRX)Grant/award (A): 680 @ $8.27EDGAR
2023-03-024BIOCRYST PHARMACEUTICALS INC (BCRX)Grant/award (A): 635 @ $8.85EDGAR
2022-12-024BIOCRYST PHARMACEUTICALS INC (BCRX)Grant/award (A): 421 @ $13.36EDGAR
2022-09-024BIOCRYST PHARMACEUTICALS INC (BCRX)Grant/award (A): 404 @ $13.90EDGAR
2022-07-074IDERA PHARMACEUTICALS, INC. (IDRA)Grant/award (A): 124,000 (derivative) @ $0EDGAR
2022-06-094BIOCRYST PHARMACEUTICALS INC (BCRX)Grant/award (A): 12,866 @ $0 · Grant/award (A): 30,022 (derivative) @ $0EDGAR
2022-06-064Aclaris Therapeutics, Inc. (ACRS)Option exercise (M): 3,356 · Grant/award (A): 15,750 (derivative) @ $0 · Grant/award (A): 4,507 (derivative) @ $0 · Option exercise (M): 3,356 (derivative) @ $0EDGAR
2022-04-044IDERA PHARMACEUTICALS, INC. (IDRA)Grant/award (A): 99,000 (derivative) @ $0EDGAR
2022-01-264IDERA PHARMACEUTICALS, INC. (IDRA)Grant/award (A): 25,000 (derivative) @ $0EDGAR
2021-11-244BIOCRYST PHARMACEUTICALS INC (BCRX)Purchase (P): 7,500 @ $12.19EDGAR
2021-07-284BIOCRYST PHARMACEUTICALS INC (BCRX)Grant/award (A): 66,667 (derivative) @ $0EDGAR
2021-07-124IDERA PHARMACEUTICALS, INC. (IDRA)Grant/award (A): 124,000 (derivative) @ $0EDGAR
2021-06-044Aclaris Therapeutics, Inc. (ACRS)Grant/award (A): 12,250 (derivative) @ $0 · Grant/award (A): 3,356 (derivative) @ $0EDGAR
2021-01-124IDERA PHARMACEUTICALS, INC. (IDRA)Sale (S): 3,210 @ $4.20 · Grant/award (A): 95,000 (derivative) @ $0EDGAR
2021-01-114IDERA PHARMACEUTICALS, INC. (IDRA)Sale (S): 2,740 @ $3.91EDGAR
2020-12-224IDERA PHARMACEUTICALS, INC. (IDRA)Grant/award (A): 128,170 @ $0 · Sale (S): 37,169 @ $4.32EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-12-17 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1187159 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs